Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

NCT01565096 is registered in ClinicalTrials.gov with ikfe-CRO GmbH as lead sponsor.

NCT NCT01565096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01565096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
Lead sponsor
ikfe-CRO GmbH
Phase
Phase 4
Overall status
Unknown status
Start date
November 30, 2011
Completion date
Not reported
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type ii